Weight Control at WeightControl.com

Ohio State University Studies Changes in Food Waste Among New Weight Loss Drug Users

When an increasingly large segment of consumers is buying less food and perhaps wasting less food, it can reverberate through the food system

WeightControl.com Interview with:
Brian E. Roe, Ph.D.
Associate Chair
Fred N. VanBuren Professor of Farm Management
The Ohio State University

WeightControl.com: What is the background for this study?

Response: The use of anti-obesity medications (AOMs) is on the rise in the United States with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists to the pharmaceutical market. It is estimated that 6% of the U.S. adult population is on a GLP-1 medication while as many as 12% have been on one at some point. While it is well-documented that people eat less food when on the drug, little is known about its impact on how much food consumers waste, which is critical because about a third of food purchased is never consumed.

Patients Who Stopped Tirzepatide (Mounjaro™) For Weight Control Gradually Regained Most of Lost Weight

Obesity is a chronic disease, like diabetes and hypertension. If treatment is discontinued, it will relapse, though gradually.

WeightControl.com Interview with:
Louis J Aronne M.D.
Sanford I. Weill Professor of Metabolic Research
Department of Medicine
Weill Cornell Medicine

WeightControl.com: What is the background for this study? What are the main findings?

Response: The SURMOUNT -4 trial demonstrates that patients who discontinued tirzepatide after losing 20.9% over 36 weeks regained about half the weight in one year to an average 9.5% weight loss following discontinuation while those who continued lost an additional 5%.

The metabolic parameters which had improved with weight loss returned towards their starting point, but did not completely regress.